True

doi:10.1038/sj/leu/2401361

Leukemia

1999

DOI: 10.1038/sj/leu/2401361

|View full text |Cite

True

Abstract: The best characterized resistance mechanism in adult acute myeloid leukemia (AML) is the one mediated by the MDR1 gene which has been shown to be associated with poor outcome. However, alternative proteins such as the more recently recognized multidrug-associated protein (MRP1), may also contribute to the resistance to anthracyclines and etoposide in AML. Recently, the role of this protein was discussed and was unclear in AML. However, recent data concerning the functionality and the modulation of the activity… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

Schaich¹,

Soucek²,

Thiede³

et al. 2005

Br J Haematol

155

View full text Add to dashboard Cite

Summary Multi drug resistance (MDR) is a major obstacle for cancer therapy. The three major candidates accounting for the development of MDR in acute myeloid leukaemia (AML) are multi drug resistance gene (MDR1), multi drug resistance‐related protein gene (MRP1) and lung resistance protein gene (LRP). So far, the differential impact of resistance gene expression on treatment outcome in AML is not clear. Therefore, we examined MDR1, MRP1 and LRP gene expression at diagnosis in 331 adult AML patients in the context of other known prognostic factors, such as age, disease status, cytogenetics and FMS‐like tyrosine kinase 3 (FLT3)‐internal tandem duplication mutational status. Median observation time was longer than 5 years [64·1 months (40·0–87·6)]. MDR1 expression proved to be an independent prognostic factor for outcome of induction therapy (P < 0·001) and overall survival (P = 0·02), whereas MRP1 expression was an independent predictor for disease‐free survival (P = 0·01) in the multivariate analysis. This prognostic impact of both resistance genes was also found in patients with intermediate risk cytogenetics. LRP expression, however, had no impact on treatment outcome in AML. Our study shows that resistance gene expression should be considered together with age, cytogenetics and FLT3 mutational status for risk‐adapted treatment strategies in AML in the future.

show abstract

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

Schaich¹,

Soucek²,

Thiede³

et al. 2005

Br J Haematol

155

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

True

Cited by 1 publication

References 32 publications

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

Contact Info

Product

Resources

About